KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $9.2 billion.

  • Royalty Pharma's Total Non-Current Liabilities rose 1858.13% to $9.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 billion, marking a year-over-year increase of 1858.13%. This contributed to the annual value of $7.9 billion for FY2024, which is 2495.94% up from last year.
  • As of Q3 2025, Royalty Pharma's Total Non-Current Liabilities stood at $9.2 billion, which was up 1858.13% from $8.4 billion recorded in Q2 2025.
  • Royalty Pharma's 5-year Total Non-Current Liabilities high stood at $9.2 billion for Q3 2025, and its period low was $6.3 billion during Q3 2023.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $7.3 billion (2022), whereas its average is $7.4 billion.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 1362.32% in 2023, then soared by 2495.94% in 2024.
  • Royalty Pharma's Total Non-Current Liabilities (Quarter) stood at $7.3 billion in 2021, then increased by 0.25% to $7.3 billion in 2022, then fell by 13.57% to $6.3 billion in 2023, then rose by 24.96% to $7.9 billion in 2024, then grew by 17.22% to $9.2 billion in 2025.
  • Its Total Non-Current Liabilities stands at $9.2 billion for Q3 2025, versus $8.4 billion for Q2 2025 and $7.8 billion for Q1 2025.